Sarit E Assouline

13PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer diagnosisKnowledge representation and reasoning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Jan 27, 2026
Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Sita Bhella, Gerard Agbayani, Katrina Hueniken

|Aug 18, 2025
Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort.

Sarah Matarasso Greenfeld, Svetlana Dmitrienko, Ian Shrier

|Mar 12, 2025
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.

Lambert Busque, Marc-Étienne Beaudet, Michaël Harnois

|Feb 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

Arnon P Kater, Rosemary Harrup, Thomas J Kipps

Pageof 3

Frequent Collaborators

5 joint publications

Lihua E Budde

4 joint publications

Nancy L Bartlett

4 joint publications

Matthew J Matasar

3 joint publications

Chan Yoon Cheah